ANN ARBOR, Mich., Nov. 30, 2007 (PRIME NEWSWIRE) -- MIR Preclinical Services (MIR) is increasing its in vitro service offerings to include evaluation of cell lines and tissue samples for target protein expression, modulation and activation status, determination of cytokine levels, and antiproliferation and cytotoxicity assays (IC50). The Company will also offer custom biochemistry and cell biology services to meet clients' specific needs.
Daniel Everdeen has recently joined MIR as Manager of in vitro services. Mr. Everdeen has over 21 years of Biochemistry and Molecular Biology experience. Dan has 18 years of drug discovery experience in the pharmaceutical industry, most recently with Pharmacia and Pfizer. His extensive experience encompasses a large variety of assays and technologies across a broad spectrum of therapeutic areas.
"I'm excited to be joining an experienced group of oncology researchers with a reputation for providing quality imaging and in vivo pharmacology services," Mr. Everdeen stated. "Our goal is to apply a more integrated suite of services to the evaluation of drug candidates while maintaining the highly personalized service that MIR's clients have come to expect and enjoy. The in vitro services group will enable our clients to gather preliminary data to support in vivo pharmacology and imaging studies. The technologies we offer will allow our clients to monitor drug induced biomarker changes and target modulation, either in cell culture or in tissues harvested from ongoing in vivo studies. We will also be able to run special request and customizable assays as well. Our group will also offer a variety of assays including cytokine profiling, cell adhesion, and biomarker analysis to support our growing inflammation pharmacology business."
About MIR Preclinical Services
MIR is a contract research organization specializing in the preclinical assessments and evaluation of novel anti-cancer and anti-inflammatory therapeutic agents. The company's senior leadership has over 100 years of drug discovery experience with models of cancer and inflammatory diseases. MIR offers many services that include analysis of efficacy, pharmacodynamics, pharmacokinetics, blood chemistries and histology. This is in addition to non-invasive imaging of disease status at anatomical and functional levels and consulting. MIR is a leader in the integration of traditional efficacy testing with clinically relevant imaging technologies to provide new insights to drug discovery and development. The company is unique in its ability to apply non-invasive in vivo imaging modalities including preclinical MRI, X-ray micro-CT, high resolution preclinical PET, and bioluminescence and fluorescence imaging to visualize biological processes such as signal transduction, apoptosis, angiogenesis, bone deformation, joint degradation and tumor growth. MIR actively collaborates with leading scientists in academia in developing new drug evaluation technologies with a view to publication of results in peer reviewed journals.